JPEN J Parenter Enteral Nutr November 2013 vol. 37 no. 6 787-793
Ding-You Li, MD, PhD1,2; Min Yang, MD, PhD3; Sarah Edwards, DO1,2; Shui-Qing Ye, MD; hD1,2,4
1Division of Gastroenterology, Children’s Mercy Hospital, University of Missouri School of Medicine, Kansas City, Missouri
2Department of Pediatrics, Children’s Mercy Hospital, University of Missouri School of Medicine, Kansas City, Missouri
3Department of Gastroenterology, Guangzhou Women and Children’s Medical Center, Guangzhou, China
4Department of Biomedical and Health Informatics, University of Missouri School of Medicine, Kansas City, Missouri
Ding-You Li, MD, PhD, Division of Gastroenterology, Departments of Pediatrics, Children’s Mercy Hospitals and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA. Email: dyli at cmh.edu.
Nonalcoholic fatty liver disease (NAFLD) is a major clinical consequence for people with obesity and metabolic syndrome and is also associated with enteral and parenteral nutrition. Early studies suggested that altered gut microbiota might contribute to obesity by affecting energy harvest from the diet and energy storage in the host.
Recent evidence in humans as well as in animal models has linked gut microbiota to the development of NAFLD through the gut-liver axis.
With bacterial overgrowth and increased intestinal permeability observed in patients with NAFLD and in animal models, gut-derived bacterial products such as endotoxin (lipopolysaccharide) and bacterial DNA are being delivered to the liver through the portal vein and then activate Toll-like receptors (TLRs), mainly TLR4 and TLR9, and their downstream cytokines and chemokines, leading to the development and progression of NAFLD.
Given the limited data in humans, the role of gut microbiota in the pathogenesis of NAFLD is still open to discussion. Prebiotics and probiotics have been attempted to modify the microbiota as preventive or therapeutic strategies on this pathological condition. Their beneficial effects on NALFD have been demonstrated in animal models and limited human studies. However, prospective, appropriately powered, randomized, controlled clinical trials are needed to determine whether prebiotics and probiotics and other integrated strategies to modify intestinal microbiota are efficacious therapeutic modalities to treat NALFD.
- Antibiotics and Vitamin D are associated with many of the same diseases
- Strong association of non alcoholic fatty liver disease and low vitamin D
- Half of obese children had fatty liver and low vitamin D – March 2014
Note: antibiotics might increase risk of both fatty liver AND Obesity
- All items in category Liver and Vitamin D
- Search for Fatty Liver in VitaminDWiki 129 items Dec 2014Nonalcoholic Fatty Liver Disease perhaps due to gut microbiota – Nov 2013
2932 visitors, last modified 08 Jan, 2015,